Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Wed Apr 02 01:29:40 GMT 2025
by
admin
on
Wed Apr 02 01:29:40 GMT 2025
|
| Protein Type | MONOCLONAL ANTIBODY |
| Protein Sub Type | IGG4 |
| Sequence Origin | HUMANIZED MOUSE |
| Sequence Type | COMPLETE |
| Record UNII |
FP2PL0HRK8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
12352
Created by
admin on Wed Apr 02 01:29:40 GMT 2025 , Edited by admin on Wed Apr 02 01:29:40 GMT 2025
|
PRIMARY | |||
|
300000041555
Created by
admin on Wed Apr 02 01:29:40 GMT 2025 , Edited by admin on Wed Apr 02 01:29:40 GMT 2025
|
PRIMARY | |||
|
C188574
Created by
admin on Wed Apr 02 01:29:40 GMT 2025 , Edited by admin on Wed Apr 02 01:29:40 GMT 2025
|
PRIMARY | |||
|
JK-103
Created by
admin on Wed Apr 02 01:29:40 GMT 2025 , Edited by admin on Wed Apr 02 01:29:40 GMT 2025
|
PRIMARY | |||
|
1799706-87-8
Created by
admin on Wed Apr 02 01:29:40 GMT 2025 , Edited by admin on Wed Apr 02 01:29:40 GMT 2025
|
NO STRUCTURE GIVEN | |||
|
FP2PL0HRK8
Created by
admin on Wed Apr 02 01:29:40 GMT 2025 , Edited by admin on Wed Apr 02 01:29:40 GMT 2025
|
PRIMARY |
| From | To |
|---|---|
| 1_22 | 1_96 |
| 2_22 | 2_96 |
| 2_132 | 4_219 |
| 2_145 | 2_201 |
| 2_259 | 2_319 |
| 1_132 | 3_219 |
| 2_365 | 2_423 |
| 3_23 | 3_93 |
| 3_139 | 3_199 |
| 4_23 | 4_93 |
| 4_139 | 4_199 |
| 1_145 | 1_201 |
| 1_224 | 2_224 |
| 1_227 | 2_227 |
| 1_259 | 1_319 |
| 1_365 | 1_423 |
| Glycosylation Type | MAMMALIAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_295 |
| N | 2_295 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
Binds to key residues in the C?terminal regions of TGF?? and epiregulin, preventing their binding to the EGFR. Engagement of the 2 targets by LY results in internalization of the transmembrane precursors and neutralization of the activity of the mature ligands in vitro.
|
||
|
TARGET -> INHIBITOR |
Binds to key residues in the C?terminal regions of TGF?? and epiregulin, preventing their binding to the EGFR. Engagement of the 2 targets by LY results in internalization of the transmembrane precursors and neutralization of the activity of the mature ligands in vitro.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|